Amgen presents new Repatha data at AHA 2026 on cost and cardiovascular risk

Amgen said on November 9, 2026 that it had presented new data on Repatha (evolocumab) at the American Heart Association Scientific Sessions 2026. The findings concern high-risk patients, with and without a prior heart attack or stroke, and the value of treating them with Repatha earlier in the cardiovascular risk continuum.

The first independent health economic analysis using detailed data from individual participants in the Phase 3 VESALIUS-CV trial compared treatment costs with health benefits. The Duke Clinical Research Institute led the analysis, in collaboration with the TIMI Study Group at Mass General Brigham and Harvard.

A separate analysis found adding Repatha to standard therapy highly cost-effective versus standard therapy alone in adults living with atherosclerotic cardiovascular disease (ASCVD).

In a pre-specified VESALIUS-CV analysis, patients with chronic kidney disease (CKD) and no prior heart attack or stroke had an approximately 90% higher rate of coronary heart disease death, heart attack or ischemic stroke (3-P MACE) than patients without CKD. Over a median follow-up of 4.6 years, Repatha lowered 3-P MACE rates in people with CKD by 39%, 4-P MACE by 23%, and the risk of all-cause death by 29%.

Amgen also presented a new analysis comparing patients treated with Repatha in the FOURIER trial and its open-label extension with a non-randomized external control drawn from UK health records. Over a maximum follow-up of more than 8 years, Repatha was associated with a 29% lower rate of 3-P MACE and a 25% lower risk of cardiovascular death. Murdo Gordon, executive vice president of Global Markets and Policy at Amgen, said the findings add to the evidence of Repatha's benefit to patients.